BIOMAT Database Logo BIOMAT Database Logo

Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months. 1993

R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
Gastroenterology Unit, Hospital Central de Asturias, School of Medicine, Oviedo, Spain.

This randomised, controlled trial was designed to assess the response to a nine month course of interferon (IFN) alfa-2b, starting with a higher than usual dose. Forty eight patients received IFN 5 million units (MU) three times a week for eight weeks followed by 3 MU three times weekly for seven months; 25 patients in the control group received no treatment. The overall response to treatment was 68.7%, an improvement over other studies, but the high rate of relapse (85% in patients who responded) suggested that a nine month treatment period was insufficient in most cases. Histological improvement was seen in more than 80% of responders to interferon, including a reduction in inflammatory activity, necrosis, and fibrosis.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500

Related Publications

R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
Treatment of chronic hepatitis C with recombinant interferon alfa-2b.
January 1993, Gut,
R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
[Long term/intermittent treatment of chronic hepatitis C with recombinant interferon alfa-2b].
September 1995, Nihon rinsho. Japanese journal of clinical medicine,
R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
Treatment of chronic hepatitis C with recombinant interferon alfa.
January 1991, The Italian journal of gastroenterology,
R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
Treatment of chronic hepatitis C with recombinant interferon alfa.
January 1992, The Western journal of medicine,
R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
Treatment of chronic hepatitis B and hepatitis C with interferon alfa-2b.
October 1996, American family physician,
R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
Recombinant interferon alfa-2b treatment in chronic non-A, non-B/type C hepatitis.
January 1993, Gut,
R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
Treatment of chronic hepatitis C with recombinant interferon alpha 2b.
October 1992, Journal of chemotherapy (Florence, Italy),
R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
Treatment of acute hepatitis C with interferon alfa-2b.
April 2002, The New England journal of medicine,
R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
Treatment of acute hepatitis C with interferon alfa-2b.
April 2002, The New England journal of medicine,
R Pérez, and R Pravia, and A Linares, and M González, and M Rodríguez, and J L Lombraña, and S Riestra, and A Suárez, and L Rodrigo
Treatment of acute hepatitis C with interferon alfa-2b.
April 2002, The New England journal of medicine,
Copied contents to your clipboard!